US2014004136A1PendingUtilityA1
Phosphorylated derivatives of a u1-70k peptide and their use in the treatment of autoimmune pathologies
Est. expirySep 18, 2021(expired)· nominal 20-yr term from priority
Inventors:Sylviane MullerFanny Sylvie Michele MonneauxJean-Paul BriandGilles GuichardJean-Gerard Guillet
A61P 37/06A61P 37/00A61P 37/02A61P 3/10A61P 29/00A61P 25/00A61P 31/22A61P 17/02A61P 19/04C07K 14/47A61P 19/02A61K 38/00A61P 1/04
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Derivatives of the peptide corresponding to the sequence RIHMVYSKRSGKPRGYAFIEY (SEQ ID NO: 1), pharmaceutical compositions, and methods of use thereof are provided.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical composition comprising an effective amount of an isolated peptide having the amino acid sequence as set forth in SEQ ID NO:1, wherein the peptide has at least one post-translational-type amino acid modification, or salt thereof, in combination with a pharmaceutically acceptable vehicle.
2 . The composition of claim 1 , wherein the composition comprises at least 200 μg of the isolated peptide or salt thereof.
3 . The composition of claim 1 , wherein the serine at position 10 of SEQ ID NO: 1 is phosphorylated.
4 . The composition of claim 1 , wherein the serine at position 7 of SEQ ID NO: 1 is phosphorylated.
5 . The composition of claim 1 , wherein the serine at position 7 and the serine at position 10 of SEQ ID NO: 1 are phosphorylated.
6 . The composition of claim 1 , wherein the serine at position 10 of SEQ ID NO: 1 is phosphorylated, and the lysine in position 8 is acetylated.
7 . The composition of claim 1 , wherein the serine at position 10 of SEQ ID NO: 1 is phosphorylated, and the lysine in position 12 is acetylated.
8 . The composition of claim 1 , wherein the serine at position 10 of SEQ ID NO: 1 is phosphorylated, and the lysine at position 8 and the lysine at position 12 are acetylated.
9 . The composition of claim 1 , wherein the serine at position 7 and the serine at position 10 of SEQ ID NO: 1 are phosphorylated, and the lysine in position 8 is acetylated.
10 . The composition of claim 1 , wherein the serine at position 7 and the serine at position 10 of SEQ ID NO: 1 are phosphorylated, and the lysine in position 12 is acetylated.
11 . The composition of claim 1 , wherein the serine at position 7 and the serine at position 10 of SEQ ID NO: 1 are phosphorylated, and the lysine in position 8 and the lysine in position 12 are acetylated.
12 . A pharmaceutical composition comprising an effective amount of an isolated peptide having the amino acid sequence as set forth in SEQ ID NO:1, wherein the peptide has at least one post-translational-type amino acid modification, or salt thereof, wherein the peptide is lyophilized.
13 . The composition of claim 11 , wherein the composition comprises at least 200 μg of the lyophilized isolated peptide or salt thereof.
14 . The composition of claim 11 , wherein the serine at position 10 of SEQ ID NO: 1 is phosphorylated.
15 . The composition of claim 11 , wherein the serine at position 7 of SEQ ID NO: 1 is phosphorylated.
16 . The composition of claim 11 , wherein the serine at position 7 and the serine at position 10 of SEQ ID NO: 1 are phosphorylated
17 . A pharmaceutical composition comprising in unitary dosage form at least 200 μg of a lyophilized isolated peptide having the amino acid sequence as set forth in SEQ ID NO:1, wherein the peptide has at least one post-translational-type amino acid modification, or salt thereof.
18 . The composition of claim 17 , wherein the serine at position 10 of SEQ ID NO: 1 is phosphorylated.
19 . The composition of claim 17 , wherein the serine at position 7 of SEQ ID NO: 1 is phosphorylated.
20 . The composition of claim 17 , wherein the serine at position 7 and the serine at position 10 of SEQ ID NO: 1 are phosphorylatedCited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.